Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience

Published:2015-02-09 Issue:43 Volume:34 Page:5411-5417
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Gao J,He Q,Subudhi S,Aparicio A,Zurita-Saavedra A,Lee D H,Jimenez C,Suarez-Almazor M,Sharma P

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc20155.pdf

Reference42 articles.

1. Leach DR, Krummel MF, Allison JP . Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734–1736.

2. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793–800.

3. Krummel MF, Allison JP . CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459–465.

4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723.

5. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517–2526.

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer immunotherapy-associated endocrine complications and treatment strategies;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

2. Recruiting T‐Cells toward the Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co‐Delivery of Cytokines and Immune Checkpoint Antibodies with Macrophage‐Membrane‐Camouflaged Nanovesicles;Advanced Materials;2023-05-04

3. Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach;Life Sciences;2023-04

4. Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction;International Journal of Molecular Sciences;2023-02-16

5. Cancer Immunotherapy;Holland‐Frei Cancer Medicine;2022-10-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3